Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial compares HLX11 to EU-Perjeta (pertuzumab) as neoadjuvant therapy for HER2-positive, hormone receptor-negative breast cancer. The study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-negative Breast Cancer

Drugs mentioned

• EU-Perjeta (pertuzumab)
• HLX11

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Breast Cancer, Breast Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING